Molecular mechanisms of action of selected steroids in breast cancer cells by Voňka, Petr et al.
Trends in Natural Product Research – PSE Young Scientists’ Meeting 





Molecular mechanisms of action of selected steroids in breast cancer 
cells 
 
Petr Voňka1,2*, Lucie Rárová3, Václav Bazgier2,4, Karel Berka4,5, Miroslav Kvasnica2, Jana 
Oklešťková2, Eva Kudová6, Miroslav Strnad2, Dalibor Valík1 and Roman Hrstka1,2 
 
1 RECAMO, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic.  
2 Laboratory of Growth Regulators, Institute of Experimental Botany AS CR & Palacký University Olomouc, 
Šlechtitelů 27, 783 71 Olomouc, Czech Republic.  
3 Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological and Agricultural 
Research, Palacký University Olomouc, Šlechtitelů 27, 783 71 Olomouc, Czech Republic. 
4 Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, třída 17. listopadu 12, 771 
46 Olomouc, Czech Republic.  
5 Regional Centre of Advanced Technologies and Materials, Department of Physical Chemistry, Palacký University 
Olomouc, třída 17. listopadu 1131, 779 00 Olomouc, Czech Republic.   
6 Institute of Organic Chemistry and Biochemistry AS CR, Flemingovo náměstí 2, 166 10 Praha 6, Czech Republic. 
*E-mail: petrvonka1@gmail.com 
 
Oestrogen receptors (ERs) represent key biomarker for breast cancer, and their status 
significantly influences disease prognosis and treatment regimens. Unique library 
consisting of approximately 8000 steroids derived from natural compounds, e.g. 
brassinosteroids, with described synthetic pathways was used to find potential ligands 
for ERs in order to predict compounds that may block their activity. 
Two compounds, MU-5562 and MU-5611 showing similar structure motives to estrone 
have been selected as the most promising candidates showing ER inhibitory activity 
comparable to routinely used ER inhibitors tamoxifen and fulvestrant. These 
compounds stabilize ERs similarly to tamoxifen. Determination of luciferase activity 
showed reduced signals comparable to commercial inhibitors. However, 
immunochemical analysis revealed decreased AGR2 expression indicating different 
mechanism of action compared to tamoxifen. 
Inhibitory effect of these compounds on ER is probably caused by presence of double 
bond in their D ring, which protects activation of ERs by decreasing of electron density 
on keto group. This configuration blocks development of hydrogen bonds network, 
which is responsible for conformational changes of α-helix H12. 
Selected combination of computational and experimental methods represents rational 
and fast way to determine the activity of given compounds towards ERs. We believe 
that these data would be used not only in research field, but also in clinical practice. 
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